|
|
Background: The purpose of this study was to investigate the correlation between serum heat shock protein 90α (HSP90α) level and disease diagnosis and classification in children with acute myeloid leukemia (AML).
Methods: Sixty-six children with treatment-naive AML and 35 healthy controls were enrolled. Serum HSP90α levels were measured by ELISA. Serum HSP90 levels were analyzed in relation to AML diagnosis, classification, and prognosis prediction among children.
Results: Serum HSP90α in children with AML was significantly higher than that in healthy controls. The ROC curve showed that serum HSP90α had excellent diagnostic efficacy for AML, with an AUC of 0.820 (95% CI: 0.737 - 0.902). Serum HSP90α was differentially expressed in different FAB subtypes of AML, which was significantly increased in M1 and M2 subtypes. Compared with the low HSP90α level group, the proportion of BM blast (%) in the high HSP90α level group was significantly increased, and the cytogenetic risk was higher. Serum HSP90α was positively correlated with BM blast (%), but no correlation was observed with the proportion of BM monocytes, lymphocytes, and red blood cells. Children with high HSP90α levels tended to have shorter overall survival than those with low HSP90α levels.
Conclusions: HSP90 level in serum may serve as a reliable biomarker for the diagnosis of childhood AML and its subtypes, and abnormal expression may contribute to disease occurrence and progression.
DOI: 10.7754/Clin.Lab.2024.241043
|
